Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
Abstract Background The prognosis of non-small-cell lung cancer (NSCLC) with brain metastases is very poor. Currently, therapeutic methods for this patient population include whole-brain radiation therapy (WBRT), surgery, radiosurgery and systemic treatment. Epidermal growth factor receptor tyrosine...
Main Authors: | Kejun Liu, Guanming Jiang, Ailing Zhang, Zhuanghua Li, Jun Jia |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-01-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-020-6543-y |
Similar Items
-
The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer
by: Wang L, et al.
Published: (2021-03-01) -
Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis
by: Ye CY, et al.
Published: (2016-10-01) -
Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01) -
Brain metastasis in non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations: a report of seven cases and literature review
by: Puchun Er, et al.
Published: (2017-08-01) -
Efficacy of Icotinib for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified
by: Yiping ZHANG, et al.
Published: (2013-03-01)